Failure of sputum eosinophilia after eotaxin inhalation in asthma

Bumbocea, D.; Scheerens, J.; Mann, B. S.; Stirling, R. G.; Chung, K. F.
May 2004
Thorax;May2004, Vol. 59 Issue 5, p372
Academic Journal
Background: Eotaxin is a chemokine specific for eosinophils and may play an important role in eosinophil recruitment in asthma. The effects of eotaxin inhalation on sputum and blood eosinophils, exhaled nitric oxide (NO), and bronchial responsiveness were determined. Methods: Eotaxin was administered by nebulisation to asthma patients in three studies: (1) an open dose finding study with eotaxin (5, 10 and 20 μg) to two asthmatic subjects; (2) a randomized placebo controlled study with 20 μg eotaxin to five asthmatic subjects and five normal volunteers; and (3) a randomized placebo controlled study with 40 μg eotaxin to nine asthmatics. Forced expiratory volume in 1 second (FEY1), exhaled NO, and blood eosinophils were measured before and hourly for 5 hours after nebulisation and at 24 and 72 hours. Methacholine bronchial challenge and sputum induction were performed before and at 5, 24, and 72 hours after inebriation. Results: In the two placebo controlled studies there was no change in sputum eosinophil count and sputum eosinophilic cationic protein concentration after eotaxin inhalation compared with placebo. FEY1, exhaled NO, and methacholine PC20 did not change. However, high dose eotaxin (40 jig) induced an increase in sputum neutrophil count compared with placebo (pcO.O5). Conclusions: Inhaled eotaxin up to 40 jig induced no changes in sputum eosinophil count but at 40 jig it increased the sputum neutrophil count. The significance of this finding is unknown.


Related Articles

  • Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. South, Mike // Internet Journal of Pediatrics & Neonatology;2005, Vol. 5 Issue 1, p23 

    This article focuses on a study that deals with an early intervention with budesonide in mild persistent asthma. A randomized, double-blind clinical trial in 7241 patients in 32 countries was conducted to assess the effects of budesonide in patients who had mild persistent asthma for less than 2...

  • Mild persistent asthma and inhaled corticosteroids: is daily therapy really necessary? Bauchner, Howard // Archives of Disease in Childhood;Oct2005, Vol. 90 Issue 10, p1094 

    This article cites a study on the treatment of mild persistent asthma, which was published in the May 6, 2005 issue of the "Journal Watch Pediatrics and Adolescent Medicine." In this double-blind trial, researchers randomized 225 adults with mild persistent asthma to receive twice-daily inhaled...

  • Analysis. Summerton, Nick // Update;5/19/2005, Vol. 70 Issue 5, p26 

    This article presents a study to find out whether intermittent as-needed corticosteroid treatment for mild persistent asthma equivalent to regular daily treatment. Treatment with daily or intermittent corticosteroid therapy in a six-centre randomised controlled trial was conducted. After...

  • COMMENTARY: Gly/Gly and Arg/Arg genotype responses to albuterol differed in mild asthma. Abramson, Michael J. // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p43 

    The article comments on a study which discusses the use of regularly scheduled albuterol treatment in asthma. The study was underpowered to detect a statistically significant effect on exacerbations in patients with mild asthma. Although many respiratory studies focus on lung function, it is...

  • Research news.  // Update;5/19/2005, Vol. 70 Issue 5, p6 

    This article presents research news related to various diseases. Mild persistent asthma can be successfully treated with short courses of corticosteroids when needed, rather than daily therapy. The U.S. researchers found many patients with the condition already use steroids intermittently,...

  • Pairwise Comparison of Levalbuterol versus Racemic Albuterol in the Treatment of Moderate-to-Severe Asthma. Pleskow, Warren W.; Nelson, Harold S.; Schaefer, Kendyl; Claus, Raymond; Roach, James M. // Allergy & Asthma Proceedings;Nov/Dec2004, Vol. 25 Issue 6, p429 

    The object of this study is a post hoc pairwise comparison of levalbuterol versus racemic albuterol for asthma in a multicenter, double-blind, randomized, placebo-controlled clinical trial. The participants are patients ⩾12 years of age (n = 362) with FEV1 45-70% of predicted. The patients...

  • Review: cardioselective β blockers do not produce adverse respiratory effects in COPD. Salpeter, S. // Evidence Based Medicine;Jun2006, Vol. 11 Issue 3, p84 

    The article presents a study that examines whether cardioselective beta blockers can cause adverse respiratory effects in patients with chronic obstructive pulmonary disease. In this study, meta analysis showed that a single dose of cardioselective beta blockers was not associated with a change...

  • Steroid Response in Stable Chronic Obstructive Pulmonary Disease. Mendella, L. A.; Manfreda, J.; Warren, C. P. W.; Anthonisen, N. R. // Annals of Internal Medicine;Jan82, Vol. 96 Issue 1, p17 

    Compares a two-week course of methylprednisolone with placebo in a double-blind crossover trial in patients with stable chronic obstructive pulmonary disease. Baseline lung function in patients with chronic obstructive pulmonary disease; Criteria for differentiating patients who respond to...

  • Roflumilast of value in very severe COPD.  // PharmacoEconomics & Outcomes News;8/25/2007, Issue 535, p10 

    The article discusses a research on the cost effectiveness of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease (COPD). It references a study by Rutten-van Möken et al, published in "PharmacoEconomics." Researchers evaluated the cost effectiveness of...


Read the Article


Sign out of this library

Other Topics